AllSight
ASTH · SERVICES-MANAGEMENT CONSULTING SERVICES · 8-K · Item 2.02 · Aug 6, 2026

Profitability beat expectations and lifted the 2026 EBITDA floor

Astrana Health, Inc. (ASTH) — AllSight decodes this SEC 8-K in plain English, versus what the market expected.

The quarter was better on earnings than on revenue. Published consensus called for roughly $0.34 of EPS and $985.6 million of revenue; Astrana delivered $0.40 of diluted GAAP EPS and $972.5 million of revenue. That is a modest EPS beat but a roughly 1% revenue shortfall versus the published estimate.

MetricQ2 2026Q2 2025 / expectation
Revenue$972.5M$654.8M; published expectation $985.6M
Diluted GAAP EPS$0.40$0.19; consensus $0.34
Adjusted EPS$0.80$0.55
Adjusted EBITDA$68.9M$48.1M; prior company guide $65M-$70M
Free cash flow, six months$92.9M$103.0M

Underlying profitability clearly outperformed the standing company bar. Adjusted EBITDA rose 43% year over year to $68.9 million, landing above the midpoint of the prior $65 million-$70 million quarterly guide, while adjusted EPS increased to $0.80 from $0.55. Revenue grew 49% to $972.5 million, but the adjusted EBITDA margin remained approximately 7%, so the earnings upside came more from scale and operating execution than from a major margin expansion. (Summary of Selected Financial Results; Reconciliation of Net Income to EBITDA and Adjusted EBITDA)

Management raised the quality of the full-year outlook, but not the growth top line. Full-year revenue guidance stayed at $3.8 billion-$4.1 billion and free-cash-flow guidance stayed at $105 million-$132.5 million. Adjusted EBITDA guidance moved from $250 million-$280 million to $255 million-$280 million, lifting only the low end by $5 million rather than raising the ceiling. That is a constructive revision, but it signals incremental confidence rather than a wholesale reset. (Guidance; Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA)

Cash generation was the main softer spot. Six-month operating cash flow fell to $100.8 million from $107.5 million, and free cash flow declined to $92.9 million from $103.0 million despite much higher earnings. Cash also fell to $400.8 million from $429.5 million at year-end, although debt repayment reduced long-term debt by roughly $102 million. The filing attributes no single definitive cause for the cash-flow decline, so the earnings beat does not yet translate into stronger year-to-date cash conversion. (Cash Flow statement; Balance Sheet Highlights)

Net read: a real but not dramatic positive surprise. The market received a modest GAAP EPS beat, an adjusted-earnings beat against the prior operating guide, and a higher EBITDA guidance floor. Those positives outweigh the small revenue miss and weaker cash conversion, while the unchanged revenue and free-cash-flow outlook limits how much the filing changes the broader 2026 picture.

Read the original 8-K on SEC EDGAR ↗
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.